Q

Quest Clinical Research | San Francisco, CA

Research site
(Unclaimed)
Location
2300 Sutter Street, Suite 202, San Francisco, California, United States of America
Site insights

Top conditions

Hepatitis (27 trials)

Hepatitis A (23 trials)

Hepatitis C (21 trials)

HIV Infections (21 trials)

Chronic Hepatitis C (12 trials)

Top treatments

Sofosbuvir
Ribavirin
Interferon
Peginterferon
Budigalimab
Daclatasvir
Bevirimat
Valganciclovir
Leronlimab
ABI-H2158

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

10 of 88
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337
Locations recently updated

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Enrolling
Human Immuno-deficiency Virus (HIV) Disease
Drug: Budigalimab
Drug: Placebo for Budigalimab

This is a first in human (FIH), multi-center, dose-finding, and dose-escalation Phase I clinical study of RO7565020 to investigate the safety and tol...

Enrolling
Chronic Hepatitis B
Drug: Nucleos(t)ide analogue (NUC) treatment
Drug: RO7565020

This is a study designed to evaluate the safety, tolerability and efficacy of New Molecular Entity (NME) combination therapies in Chronic Hepatitis B...

Active, not recruiting
Hepatitis B, Chronic
Drug: PD-L1 LNA (RO7191863)
Drug: PEG-IFN

This study is a Phase 2b/3 multi-center extension study designed to evaluate the long term antiviral activity, safety, and tolerability of the strate...

Active, not recruiting
HIV-1-infection
Drug: PRO 140 700
Drug: PRO 140 350

Participants who receive EBT-101 in a parent protocol will be eligible to participate in this long-term follow-up (LTFU) study (EBT-101-002).

Invitation-only
HIV-1-infection
Biological: EBT-101

The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.

Active, not recruiting
HIV
Genetic: SB-728mR-HSPC Infusion 3 days following busulfan conditioning

This is a First in Human (FIH) study of EBT-101 administered IV to aviremic HIV-1 infected adults on stable antiretroviral therapy (ART).

Enrolling
HIV-1-infection
Biological: EBT-101

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: PTM CILO/FIR
Drug: Cilofexor (CILO)/Firsocostat (FIR)

TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere...

Enrolling
HIV-1-infection
Drug: TMB-365/TMB-380

Trial sponsors

Gilead Sciences logo

Gilead Sciences (11 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems